Abstract
Capecitabine and oxaliplatin (CAPOX) plus bevacizumab (BEV) therapy (CAPOX/BEV) is a standard treatment recommended as the first-line treatment for colorectal cancer recurrence. Recently, sinusoidal obstruction syndrome (SOS) and resulting portal hypertension have been reported as important side effects of oxaliplatin. We herein report a rectal cancer patient who underwent percutaneous transhepatic stoma variceal embolization (PTO) and partial splenic artery embolization (PSE) for stomal variceal bleeding and splenomegaly due to portal hypertension caused by SOS after CAPOX therapy. A 43-year-old man who underwent robot-assisted laparoscopic abdominoperineal resection for advanced lower rectal cancer was started on CAPOX/BEV therapy for early recurrence 1 month after surgery. In the sixth course, splenomegaly rapidly worsened, stomal varices appeared, and the stoma began bleeding. At 5 months after the appearance of stomal varices, the splenomegaly worsened, the frequency of stomal bleeding increased, and PTO was performed. Five months later, PSE was performed for splenomegaly and thrombocytopenia. At 5 months since the PSE, the stoma bleeding has not recurred, and the thrombocytopenia has been corrected. The patient has been able to continue chemotherapy. We suggest that staged treatment by PTO and PSE be considered an important treatment option for stomal varices and splenomegaly associated with SOS.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
CAPOX therapy is a standard treatment recommended as adjuvant chemotherapy and primary treatment for recurrence of colorectal cancer, but sinusoidal obstruction syndrome (SOS) has been reported as an important side effect of oxaliplatin [1, 2]. SOS reportedly causes fibrosis and stenosis of sinusoids, which eventually leads to portal hypertension [3, 4], and portal hypertension increases inferior mesenteric vein (IMV) pressure, resulting in the appearance of stoma varicose veins [5].
We herein report a case of rectal cancer in which percutaneous transhepatic stoma variceal embolization (PTO) and partial splenic artery embolization (PSE) were performed due to stomal varices caused by portal hypertension induced by SOS after oxaliplatin administration.
Case report
A 43-year-old man was diagnosed with advanced lower rectal cancer (Rb, cT4b, cN3, cM0, cStage IIIc [6]) (Fig. 1a, b) and underwent robot-assisted laparoscopic abdominoperineal resection with bilateral lymph node dissection. He had no remarkable personal or family history.
One month postoperatively, contrast-enhanced computed tomography (CT) revealed multiple enlarged left lateral lymph nodes and para-aortic lymph nodes (Fig. 2a, b), leading to the diagnosis of early recurrence, and CAPOX/BEV therapy (arm: bevacizumab 7.5 mg/kg and oxaliplatin 130 mg/m2 on day 1 and oral capecitabine 2000 mg/m2 on days 1–14, every 3 weeks) was initiated. The splenomegaly worsened rapidly after the sixth course of CAPOX, and the platelet count decreased. He had no abdominal pain suspicious of hepatomegaly and no weight gain.
Five months after starting chemotherapy, the patient developed stomal varices and began bleeding (approximately 300–500 ml each time). After nine courses of CAPOX/BEV had been administered, the neuropathy worsened, and oxaliplatin was discontinued (total dose of oxaliplatin: 1084 mg/m2). Thereafter, contrast-enhanced CT determined he had progressive disease (PD) [7], and two courses of FOLFIRI plus Aflibercept therapy were administered.
Thirteen months after starting chemotherapy, contrast-enhanced CT revealed worsening of the splenomegaly and stomal varices as well as frequent bleeding from the stoma, so the patient was admitted to the hospital for a close examination and treatment. Hematological and biochemical examinations on admission revealed a slightly low level of hemoglobin 11.0 g/dl and a platelet count of 15.2 × 104/mm3. The coagulation function and hepatobiliary enzyme levels were normal. The liver function was acceptable (Table 1).
Contrast-enhanced CT findings on admission showed a 17 × 7 cm splenomegaly (Fig. 3a) and stomal varices (Fig. 3b–d). A comparison of the CT findings at the time of early recurrence with the CT findings obtained before admission showed that the spleen index (splenic length diameter × splenic width diameter) had doubled, and the stomal varices were highly developed (Fig. 4). The thickness of the liver at the midline of the clavicle was 16 cm, suggesting mild hepatomegaly. No liver metastasis findings were observed during the disease course, and no varicose veins were observed by gastrointestinal endoscopy through the stoma.
We decided to perform a liver biopsy and percutaneous transhepatic stomal variceal embolization to investigate SOS and treat the stomal varices. We approached the stomal varices from the right branch of portal vein and performed inferior mesenteric vein (IMV) angiography. The peristomal varices were visualized from the inferior abdominal wall vein to the external iliac vein (Fig. 5a). We injected 5% Ethanolamine oleate into the peripheral stomal varices and embolized the central side with Fibered IDC coil® 5 mm × 12 cm and C-Stopper coil®0.016 180 mm × 3.
Postoperative contrast-enhanced CT revealed the disappearance of the stomal varices (Fig. 5b, c). A histopathological examination of a liver biopsy specimen demonstrated focal central vein narrowing and sinusoidal occlusion by fibrosis, consistent with sinusoidal obstruction syndrome (Fig. 6). Based on the European Society for Blood and Marrow Transplantation (EBMT) criteria, which are currently used to diagnose and classify the severity of SOS, the severity was determined to be mild [8].
We performed PSE 5 months after PTO because the splenomegaly induced thrombocytopenia made it difficult to continue chemotherapy. We punctured the right femoral artery and selectively embolized the middle and inferior pole branches of the splenic artery with Spongel®. Postoperative contrast-enhanced CT showed that the middle to lower poles of the spleen were almost entirely contrast-enhanced, except for some areas, and the embolization effect was about 80% (Fig. 7a, b). The platelet count improved quickly after PSE (Fig. 4). Four months have passed after PSE, and chemotherapy is ongoing without any recurrence of stoma bleeding.
Discussion
SOS is a systemic endothelial disease that typically presents in the days or weeks after hematopoietic cell transplantation (HCT) with refractory thrombocytopenia, hepatomegaly, ascites, and jaundice, and it can rapidly progress to multiorgan dysfunction and death. SOS develops in up to 15% of adults after HCT [9], but has also been reported as a major side effect of oxaliplatin [1, 2]. It is induced by damage to sinusoidal endothelial cells and amplified by the local inflammatory response and activation of the coagulation-fibrinolysis pathway, leading to severe hepatic necrosis [3, 4]. Regarding the underlying mechanism, oxaliplatin causes the generation of reactive oxygen species, which depletes glutathione in sinusoidal epithelial cells and increases oxidative stress [10]. In addition, oxaliplatin causes depolymerization of actin in sinusoidal epithelial cells and the upregulation of matrix metalloproteinases-2,9 which leads to fibroblast proliferation and endothelial cell loss as well as fibrosis of sinusoids and central veins, resulting in portal hypertension [1, 10,11,12,13].
The incidence of SOS after oxaliplatin administration was 48.8–59.0% [14,15,16], and SOS was reported to be found in 51% of cases of hepatic resection after neoadjuvant chemotherapy and 79% of liver biopsy specimens [1, 11], so there is concern about the high incidence of SOS. Previously, mortality from severe SOS has been reported to exceed 80% [9, 17,18,19]. In a systematic review of patients with severe SOS after hepatectomy, an increased frequency of postoperative complication rates, complications specific to liver surgery and postoperative liver failure were reported [20]. As for the relationship between the dose of oxaliplatin and the development of SOS, it has been reported that more careful follow-up is important in patients who have received more than 6 courses of oxaliplatin-based chemotherapy [21, 22]. It has been reported that splenomegaly is induced when the total oxaliplatin dose exceeds 1040 mg/mm2 and that 12 courses of FOLFOX therapy and more than 8 courses of CAPOX therapy are risk factors for the development of SOS [23]. Welsh et al. reported that postoperative complications, the reoperation rate, and the duration of hospital stay were increased in cases of hepatic resection performed after oxaliplatin administration when chemotherapy was administered for more than 12 weeks or when the time between chemotherapy discontinuation and resection was less than 4 weeks [24]. In the present case, splenomegaly worsened after the sixth course of CAPOX (oxaliplatin dose: 684 mg/m2), and stoma bleeding occurred in the eighth course. The platelet count decreased with the worsening of splenomegaly, and a liver biopsy at the time of stoma variceal embolization showed scattered fibrosis between hepatocytes and partial strong fibrosis in the central vein, which led to the diagnosis of SOS and portal hypertension.
Stomal varices occur at the border between the intestine and abdominal wall at the stoma-mucosal junction as a blood channel of the portal-systemic shunt under conditions of portal hypertension [5]. A total of 27–31% of patients with portal hypertension due to chronic liver disease reportedly develop varicose veins when colostomy is performed [25].
Since they form on or near the body surface, the site of bleeding is often easy to identify, and the bleeding-related mortality rate is as low as 3–4% [26]. However, bleeding stomal varices present with frequent bleeding and are often difficult to treat [27, 28]. In patients with metastatic multiple liver tumors and ascites, treatment options are limited. Bleeding due to varices is a complication that not only decreases the patient’s quality of life but also leads to progressive anemia, a worsened nutritional status, and a decreased performance status, making interruption of chemotherapy a prognostic factor. Management of stomal varices bleeding and thrombocytopenia due to splenomegaly has a significant impact on the quality of life and continuation of chemotherapy.
The two major elements of treatment are bleeding control of stoma varices and modification of the macrocirculation to improve portal hypertension. Local therapies for hemostasis of stoma varicose veins include compression, suturing, and sclerotherapy, but all are symptomatic, and rebleeding is inevitable. Drug therapies, such as β-blockers, octreotide, and ursodeoxycholic acid, are sometimes used prophylactically, but the efficacy of monotherapy is very limited [29, 30]. Stoma reconstruction is reported to be highly invasive and rebleeding occurs in 75% of cases [31]. Therefore, therapeutic intervention for the feeding vein is necessary. In our case, we chose the PTO approach from the feeding vein.
PTO is a feasible and safe option for stomal variceal bleeding, despite the invasiveness of transhepatic puncture [32,33,34]. Ishikawa et al. performed PTO in 37 patients with refractory hepatic encephalopathy and gastroesophageal varices and reported that the procedure was successful in all patients, with a recurrence rate of 2.7% [35]. Maciel et al. also reported that stoma variceal embolization with PTO was performed, and the bleeding subsided after 6 months of follow-up [36]. Compared with the method of percutaneous puncture and contrast of varicose veins, the overall image, including varicose veins and collateral vessels, can be grasped, which enables more efficient hemostasis by embolization [36, 37]. In the present case, we performed PTO for bleeding control. Although minimally invasive, PTO provides valuable information based on the findings of a blood flow evaluation and liver biopsy and the response rate is reported to be high. We, therefore, believe that PTO can be an important local treatment option.
After embolization of the stomal varices in our patient, the thrombocytopenia caused by splenomegaly worsened and chemotherapy could not be continued. We, therefore, also needed to address the portal hypertension. Splenectomy [38, 39], PSE [40], transjugular intrahepatic portosystemic shunt (TIPS) [3], and surgical shunt angioplasty have been reported as treatments to reduce portal pressure. PSE is useful as a method to correct abnormal splenic hyperactivity and reduce portal pressure while preserving the important splenic functions [40, 41]. A percutaneous approach through the femoral artery is feasible, and the procedure is short and minimally invasive, taking only one to two hours. It is effective in improving the liver function, decreasing variceal bleeding, treating hepatic encephalopathy, and improving blood cell counts in patients with portal hypertension [42]. A study of the acute effects of PSE on portal and visceral hemodynamics in cirrhotic patients reported that it produced an immediate portal decompression effect without decreasing portal perfusion and increased the blood flow in the hepatic artery and superior mesenteric vein, which was associated with an improved liver function [43]. Splenic abscess is an extremely serious complication, which may be triggered by post-embolization anaerobic bacterial growth, percutaneous contamination by exogenous bacteria, and retrograde infection of intestinal bacteria via portal reflux [44]. Unlike splenectomy, it is possible to selectively determine the extent of embolization. For cases of macro-splenomegaly or a poor hepatic function, it is also important to embolize in fractions from the beginning (keeping the embolization area at 30% per embolization) [40]. Since PSE has a poor immediate effect on stoma variceal bleeding, it needs to be combined with local hemostatic management [39]. After PSE in the present patient, the platelet count improved, and chemotherapy was able to be restarted. It is important to have a high index of suspicion for the diagnosis of hepatic SOS and to initiate treatment promptly. Patients with mild or moderate severity SOS generally do well with supportive care measures alone, but they must be monitored for progression to severe disease [8]. Defibrotide is a sodium salt of single-stranded oligodeoxyribonucleotides derived from DNA of the porcine intestinal mucosa [45] that was approved for the treatment of severe hepatic SOS after HCT in Japan in 2019. The mechanism of action is not well understood, but it may involve endothelial protection, restoration of the thrombo-fibrinolytic balance, and/or anti-inflammatory properties [46, 47]. Defibrotide treatment for severe SOS was associated with improved survival, according to a multicenter study of defibrotide treatment versus matched historical control patients [48], and a systematic review of 17 studies [49]. In Japan, defibrotide is currently approved only for use in severe SOS after HCT; however, the collection of further data on its use will be important because of concerns about the high incidence of SOS caused by oxaliplatin. Currently, we believe that it is better to follow patients with hepatosplenomegaly and collateral hyperplasia with attention to the risk of developing SOS under the use of oxaliplatin and to individualize the treatment as appropriate.
We searched for reports from PubMed (1950 to January 2022) using the keywords “stomal varices”, “stomal variceal”, or “stoma varix”. Among them, we extracted reports of stomal varices related to oxaliplatin-based chemotherapy in colorectal cancer cases and found six reports, including our case [5, 35, 44, 50, 51] (Table 2). There were five cases of liver metastasis, and five cases were diagnosed as SOS. All patients received oxaliplatin-based first-line chemotherapy, five patients received FOLFOX, and only our patient received CAPOX. The median cycle was 11.5 (5–13) courses. Two patients underwent variceal embolization and sclerotherapy via the percutaneous transhepatic approach. One case was treated with palliative ligation and percutaneous sclerotherapy, but rebleeding occurred, and PTO was performed later. None of them had rebleeding of stomal varices after PTO. Our patient underwent PSE, and one patient underwent TIPS for portal hypertension. The patient who underwent TIPS showed worsening of hepatic encephalopathy 6 weeks after the procedure. In our case, after direct embolization of stomal varices with PTO, PSE was safely performed to correct portal hypotension and thrombocytopenia. Five months have passed since PSE, and chemotherapy is ongoing without any recurrence of stoma bleeding.
Conclusion
We encountered a case of stomal varices due to portal hypertension caused by SOS after oxaliplatin administration that was treated by PTO and PSE. Considering the invasiveness and complications, PTO and PSE were the optimal choices. We suggest that staged treatment be considered an important treatment option for stomal varices and splenomegaly associated with SOS.
References
Rubbia-Brandt L, Audard V, Sartoretti P, et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol. 2004;15:460–6.
Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–72.
Mohty M, Malard F, Abecassis M, et al. Sinusoidal obstruction syndrome/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015;50:781.
Carreras E, Diaz-Ricart M. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant. 2011;46:1495.
Sonoda H, Morishita H, Shioaki Y. TIPS is effective for bleeding of stomal varices: report of a case. JJCS. 2015;40:144–7.
Japanese Society for Cancer of the Colon and Rectum. Japanese classification of colorectal, appendiceal, and Anal carcinoma: the 3d english edition [secondary publication]. J Anus Rectum Colon. 2019;3:175–95.
Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1). Eur J Cancer. 2009;45:228–47.
Mohty M, Malard F, Abecassis M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51:906–12.
Coppell JA, Richardson PG, Soiffer R, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16:157–68.
Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;110:2761–7.
Hubert C, Sempoux C, Horsmans Y, et al. Nodular regenerative hyperplasia: a deleterious consequence of chemotherapy for colorectal liver metastases? Liver Int. 2007;27:938–43.
Grávalos C, García-Escobar I, García-Alfonso P, et al. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II–III colorectal cancer. Oncology. 2009;76:363–8.
Deleve LD, Wang X, Tsai J, et al. Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition. Gastroenterology. 2003;123:882–90.
Colli A, Pozzoni P, Berzuini A, et al. Decompensated chronic heart failure: increased liver stiffness measured by means of transient elastography. Radiology. 2010;257:872–8.
Mukund A, Pargewar SS, Desai SN, et al. Changes in liver congestion in patients with Budd-Chiari syndrome following endovascular interventions: assessment with transient elastography. J Vasc Interv Radiol. 2017;28:683–7.
Jalal Z, Iriart X, De Lédinghen V, et al. Liver stiffness measurements for evaluation of central venous pressure in congenital heart diseases. Heart. 2015;101:1499–504.
Sakai M, Strasser SI, Shulman HM, et al. Severe hepatocellular injury after hematopoietic cell transplant: incidence, etiology and outcome. Bone Marrow Transplant. 2009;44:441.
Carreras E. How I manage sinusoidal obstruction syndrome after haematopoietic cell transplantation. Br J Haematol. 2015;168:481.
Zhao J, van Mierlo KMC, Gómez-Ramírez J, et al. Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg. 2017;104:990.
Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247:118–24.
Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7.
Poston GJ. The use of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Eur J Surg Oncol. 2005;31:325–30.
Yamaguchi K, Ryu Y, Saisho K, et al. Splenomegaly and esophageal varices associated with XELOX plus bevacizumab therapy for non-resectable advanced colon cancer : a case report. Jpn J Cancer Clin. 2014;60:447–52.
Welsh FK, Tilney HS, Tekkis PP, et al. Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer. 2007;96:1037.
Fucini C, Wolff BG, Dozois RR, et al. Bleeding from peristomal varices: perspective on prevention and treatment. Dis Colon Rectum. 1991;34:1073–8.
Bret JS, Abdullah AF, Michael R, et al. Bleeding stromal varices: case series and systematic review of the literature. Clin Gastroenterol Hepatol. 2008;6:346–52.
Kubokawa M, Akahoshi K, Kasiwabara Y, et al. Clinical characteristics of ectopic varices. JJPH. 2009;15:169–75.
Matsui S, Kudo M. The clinical characteristics, diagnosis and treatment for patients presenting with duodenal varices. JJPH. 2009;15:190–4.
Vidal V, Joly L, Perreault P, et al. Usefulness of transjugular intrahepatic portosystemic shunt in the management of bleeding ectopic varices in cirrhotic patients. Cardiovasc Intervent Radiol. 2006;29:216–9.
Conte JV, Arcomano TA, Naficy MA, et al. Treatment of bleeding varices. Report of a case and review of the literature. Dis Colon Rectum. 1990;33:308–14.
Terai S, Terada I, Shinbo T, et al. A case of bleeding stomal varices treated by percutaneous transhepatic variceral obliteration. J Jpn Surg Assoc. 2015;76:79–84.
Arulraj R, Mangat KS, Tripathi D. Embolization of bleeding stomal varices by direct percutaneous approach. Cardiovasc Intervent Radiol. 2011;34:S210–3.
Kwok AC, Wang F, Maher R, et al. The role of minimally invasive percutaneous embolization technique in the management of bleeding stomal varices. J Gastrointest Surg. 2013;17:1327–30.
Ishikawa T, Imai M, Ko M, et al. Percutaneous transhepatic obliteration and percutaneous transhepatic sclerotherapy for intractable hepatic encephalopathy and gastric varices improves the hepatic function reserve. Biomed Rep. 2017;6:99–102.
Maciel MJ, Pereira OI, Motta Leal Filho JM, et al. Peristomal variceal bleeding treated by coil embolization using a percutaneous transhepatic approach. WJCC. 2016;4:25–9.
Kishimoto K, Hara A, Arita T, et al. Stomal varices: treatment by percutaneous transhepatic coil embolization. Cardiovasc Intervent Radiol. 1999;22:523–5.
Kobayashi N, Fukuhara T, Mesaki K, et al. A case of bleeding stomal varices during the course of oxaliplatin-based chemotherapy for recurrent rectal cancer. Jpn J Cancer Chemother. 2014;41:905–7.
Luz JH, Luz PM, Marchiori E, et al. Partial splenic embolization to permit continuation of systemic chemotherapy. Cancer Med. 2016;5:2715–20.
Kato K, Nakama R, Tanimura K, et al. Treatment of refractory stomal variceal hemorrhage with partial splenic artery embolization: a case report. Interv Radiol. 2019;4:48–52.
Yoshida H, Mamada H, Taniai N, et al. Partial splenic embolization. JJPH. 2012;18:215–6.
Koconis KG, Singh H, Soares G. Partial splenic embolization in the treatment of patients with portal hypertension: a review of the english language literature. J Vasc Interv Radiol. 2007;18:463–81.
Helaly AZ, Al-Warraky MS, El-Azab GI, et al. Portal and splanchnic hemodynamics after partial splenic embolization in cirrhotic patients with hypersplenism. APMIS. 2015;123:1032–9.
Masada T, Tanaka T, Sakaguchi H, et al. Coils versus gelatin particles with or without intraarterial antibiotics for partial splenic embolization: a comparative evaluation. J Vasc Interv Radiol. 2014;25:852–8.
Theophilidou E, Waraich N, Raza T, et al. Liver metastases, a rare cause of portal hypertension and stoma bleeding. Brief review of literature. Int J Surg Case Rep. 2012;3:173–6.
Kornblum N, Ayyanar K, Benimetskaya L, et al. Defibrotide, a polydisperse mixture of single-stranded phosphodiester oligonucleotides with lifesaving activity in severe hepatic veno-occlusive disease: clinical outcomes and potential mechanisms of action. Oligonucleotides. 2006;16:105.
Richardson PG, Corbacioglu S, Ho VT, et al. Drug safety evaluation of defibrotide. Expert Opin Drug Saf. 2013;12:123.
Pescador R, Capuzzi L, Mantovani M, et al. Defibrotide: properties and clinical use of an old/new drug. Vascul Pharmacol. 2013;59:1.
Richardson PG, Riches ML, Kernan NA, et al. Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure. Blood. 2016;127:1656.
Richardson P, Aggarwal S, Topaloglu O, et al. Systematic review of defibrotide studies in the treatment of veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS). Bone Marrow Transplant. 2019;54:1951.
Yamaguchi H, Furuichi Y, Kasai Y, et al. A case of severe stenosis of hepatic veins and inferior vena cava with stomal variceal bleeding induced by oxaliplatin-based chemotherapy. Clin J Gastroenterol. 2018;11:150–5.
Uehara H, Kawanaka H, Nakanoko T, et al. Successful hybrid surgery for ileal conduit stomal varices following oxaliplatin-based chemotherapy in a patient with advanced colorectal cancer. Surg Case Rep. 2020;6:236.
Acknowledgements
We thank Japan Medical Communication for English language editing.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Mizukami, S., Shonaka, T., Tani, C. et al. A case of percutaneous transhepatic stomal varices embolization and partial splenic artery embolization for rectal cancer after CAPOX/BEV chemotherapy: the summary of the stomal varices related to oxaliplatin administration. Clin J Gastroenterol 16, 54–62 (2023). https://doi.org/10.1007/s12328-022-01720-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-022-01720-7